Loading provider…
Loading provider…
Dermatology Physician in Phoenix, AZ
NPI: 1376832196Primary Practice Location
MAYO CLINIC HOSPITAL
5777 E Mayo Blvd, Phoenix, AZ
Primary Employer
Mayo Clinic Building - Scottsdale
mayoclinic.org
HQ Phone
Get M.D. Aaron's Phone Numberphone_androidMobile
Get M.D. Aaron's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardAZ State Medical License
CO State Medical License
2024 - 2027
NV State Medical License
2024 - 2027
ID State Medical License
2024 - 2026
MT State Medical License
2024 - 2026
AZ State Medical License
2012 - 2025
NM State Medical License
2024 - 2025
WY State Medical License
2024 - 2025

American Board of Dermatology
Dermatology
Rush Medical College
rushu.rush.edu
Medical School
Until 2011
Mayo Clinic College of Medicine and Science (Scottsdale)
Residency • Dermatology
2011 - 2015
Mayo Clinic College of Medicine and Science
Internship • Transitional Year
2011 - 2012
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 341 | 652 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 180 | 219 |
| 3 | 17000Destruction of skin growth | 135 | 157 |
| 4 | 11104Punch biopsy of single skin lesion | 98 | 107 |
| 5 | 17003Destruction of 2-14 skin growths | 90 | 410 |
Authors: Thais Prota Hussein Pincelli, Jason Sluzevich, Mark Pittelkow
Journal: Br J Dermatol
Publication Date: 2022-07-15
Bexarotene: A Case Study of Medicare Part D's Specialty Drug Shortcomings.
Tumor with the features of both squamous cell carcinoma and melanoma (melanocarcinoma).
Authors: Viktoryia Kazlouskaya, Elise Kochoumian
Publication Date: 2015-05
Lead Sponsor: Mayo Clinic
Intervention / Treatment: DRUG: Deucravacitinib
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Placebo, DRUG: M5049 high dose
Lead Sponsor: Mayo Clinic
Intervention / Treatment: DRUG: Dupilumab, OTHER: Photo therapy